Syngene International Q1 FY27 earnings call

Syngene reported a significant 16% year-on-year decline in revenue from operations to INR 736 crores for Q1 FY27, primarily due to the absence of offtake from its single large customer, Zoetis, in the biologics manufacturing business. This, coupled with attrition in commoditized research services, led to an operating EBITDA of INR 91 crores and a reported Profit After Tax of negative INR 9 crores, after an exceptional charge^📎 of INR 10 crores for termination benefits. The EBITDA margin stood at 12%, impacted by lower revenues and a foreign exchange hedge loss of INR 50 crores.

FY27 is marked as a year of transition and strategic renewal under the new Managing Director and CEO, Siddharth Mittal. The company aims to reposition itself by strengthening its commercial engine, reaffirming CDMO as a primary growth driver, and moving up the value chain in discovery services through AI-led differentiation. Investments are also being made in emerging scientific modalities and clinical research capabilities to build a more diversified and resilient commercial portfolio.

Management acknowledged drifting towards commoditized research services, leading to pricing pressure and limited differentiation. The new strategy emphasizes high-value, differentiated services, particularly in large-molecule CDMO and AI-enabled drug discovery. The company is strengthening its Syn.AI platform with giga-scale virtual screening and AI-driven de novo design capabilities to accelerate and improve research outcomes.

Efforts are underway to improve capacity utilization across facilities. The Mangalore small molecule CDMO facility, which previously had low utilization, is expected to see a significant ramp-up in FY27, continuing into FY28, with new commercial and clinical molecules. The Bayview facility in the U.S. is being operationalized later this year, with initial revenues expected from FY28, and is attracting interest for both human and animal health projects.

For the full financial year FY27, Syngene anticipates a single-digit decline in revenue in rupee terms and EBITDA margins in the mid-20s. This revised guidance reflects the Q1 challenges, with management expecting H2 to be stronger due to revenue uptick and ongoing cost optimization initiatives. The company aims to return to profitable and sustainable double-digit growth from FY28 onwards, leveraging its strategic shifts and new facility contributions.

Syngene is expanding its clinical research capabilities, including early and late-phase clinical development, translational research, and bioanalytical sciences, through partnerships like the MoU with THSTI. While this segment is small, it is growing significantly and is seen as a key differentiator. However, the Indian regulatory landscape poses challenges, with lengthy approval processes for clinical trials, leading Syngene to pursue partnerships in countries like Australia and Europe to accelerate clinical development.

The company maintains a strong balance sheet with a net cash balance of INR 1,541 crores at the end of Q1 FY27. Capital expenditure for the quarter was approximately INR 70 crores, primarily directed towards the Bayview facility and technology platforms. Management emphasized continued financial discipline, cost cutting, and asset utilization to improve operational efficiency and support future growth.